Original Article

Evaluating the frequency and risk factors of multidrug-resistant bacteria in biliary samples

Abstract

Background and Objectives: This study aimed to evaluate the frequency of multidrug-resistant (MDR) bacteria in biliary samples, MDR-bacteria risk factors, and the relationship between MDR-bacteria positivity and some clinical outcomes.
Materials and Methods: The study was conducted between May 2018 and May 2023, including patients over the age of 18 who had positive culture results in biliary samples. The frequency of MDR-bacteria in biliary samples was evaluated. Risk factors for MDR bacteria were assessed using univariate and multivariate analyses. MDR and non-MDR groups were compared inappropriate empirical antibiotic treatment, total antibiotic treatment duration, length of stay, and in-hospital mortality.
Results: 342 microorganisms were isolated from 202 patients. Escherichia coli was the most commonly (37.2%) isolated Gram-negative microorganism, and Enterococcus spp. was the most commonly (70.2%) isolated Gram-positive microorganism. The incidence of MDR microorganisms was 42.3%. Gastrointestinal malignancy (OR: 1.96; 95% CI, 1.03-3.71) and previous antibiotic use (OR: 2.26; 95% CI, 1.09-4.68) were independent risk factors for MDR-bacteria. In the MDR group, inappropriate empirical antibiotic treatment (56.6% vs. 41%, p = 0.091), total antibiotic treatment duration (13 vs. 8 days, p = 0.054), length of stay (24 vs. 15 days, p = 0.001), and in-hospital mortality (27.3% vs. 22.3%, p = 0.416) were higher compared to the non-MDR group.
Conclusion: MDR-bacteria positivity is associated with inappropriate antibiotic treatment, prolonged hospitalization, and increased mortality. Screening, antibiotic prophylaxis, and empirical treatment approaches should be carefully performed in patients with malignancy and recent antibiotic use, which are significant risk factors for MDR-bacteria.

1. World Health Organization (2023). Antimicrobial resistance surveillance in Europe 2023-2021 data. https://www.who.int/europe/publications/i/item/9789289058537
2. Serra N, Di Carlo P, D'Arpa F, Battaglia E, Fasciana T, Gulotta G, et al. Human bile microbiota: A retrospective study focusing on age and gender. J Infect Public Health 2021; 14: 206-213.
3. Suh S-W, Choi YS, Choi S-H, Do JH, Oh H-C, Kim HJ, et al. Antibiotic selection based on microbiology and resistance profiles of bile from gallbladder of patients with acute cholecystitis. Sci Rep 2021; 11: 2969.
4. Reuken PA, Torres D, Baier M, Loffler B, Lubbert C, Lippmann N, et al. Risk factors for multi-drug resistant pathogens and failure of empiric first-line therapy in acute cholangitis. PLoS One 2017; 12(1): e0169900.
5. Gianotti L, Honselmann KC, Angrisani M, Gavazzi F, Keck T, Wellner U, et al. Diversified effects of bile contamination, postoperative infections, and antimicrobial resistance level on the oncologic prognosis after pancreatoduodenectomy for ductal adenocarcinoma. Anticancer Res 2022; 42: 2743-2752.
6. Sugawara G, Nagino M, Nishio H, Ebata T, Takagi K, Asahara T, et al. Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. Ann Surg 2006; 244: 706-714.
7. Bednarsch J, Czigany Z, Heij LR, Luedde T, van Dam R, Lang SA, et al. Bacterial bile duct colonization in perihilar cholangiocarcinoma and its clinical significance. Sci Rep 2021; 11: 2926.
8. Hess AS, Kleinberg M, Sorkin JD, Netzer G, Johnson JK, Shardell M, et al. Prior colonization is associated with increased risk of antibiotic-resistant Gram-negative bacteremia in cancer patients. Diagn Microbiol Infect Dis 2014; 79: 73-76.
9. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-281.
10. Ozturk-Engin D, Agalar C, Cag Y, Can FK, Balkan II, Karabay O, et al. Microorganisms isolated from the bile of the patients who have undergone cholecystectomy and their antibiotic resistance pattern: multicenter prospective study. Int Microbiol 2022; 25: 759-767.
11. Reiter FP, Obermeier W, Jung J, Denk G, Mahajan UM, De Toni EN, et al. Prevalence, resistance rates, and risk factors of pathogens in routine bile cultures obtained during endoscopic retrograde cholangiography. Dig Dis 2021; 39: 42-51.
12. Miutescu B, Vuletici D, Burciu C, Turcu-Stiolica A, Bende F, Ratiu I, et al. Identification of microbial species and analysis of antimicrobial resistance patterns in acute cholangitis patients with Malignant and Benign Biliary Obstructions: A comparative study. Medicina (Kaunas) 2023; 59: 721.
13. Amanati A, Sajedianfard S, Khajeh S, Ghasempour S, Mehrangiz S, Nematolahi S, et al. Bloodstream infections in adult patients with malignancy, epidemiology, microbiology, and risk factors associated with mortality and multi-drug resistance. BMC Infect Dis 2021; 21: 636.
14. Goel N, Nadler A, Reddy S, Hoffman JP, Pitt HA. Biliary microbiome in pancreatic cancer: alterations with neoadjuvant therapy. HPB (Oxford) 2019; 21: 1753-1760.
15. Sulis G, Sayood S, Katukoori S, Bollam N, George I, Yaeger LH, et al. Exposure to World Health Organization's AWaRe antibiotics and isolation of multidrug resistant bacteria: a systematic review and meta-analysis. Clin Microbiol Infect 2022; 28: 1193-1202.
16. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant Gram-negative infections. Clin Infect Dis 2023; ciad428.
17. MacFadden DR, Coburn B, Shah N, Robicsek A, Savage R, Elligsen M, et al. Utility of prior cultures in predicting antibiotic resistance of bloodstream infections due to Gram-negative pathogens: a multicentre observational cohort study. Clin Microbiol Infect 2018; 24: 493-499.
18. Golzarri MF, Silva-Sanchez J, Cornejo-Juarez P, Barrios-Camacho H, Chora-Hernandez LD, Velazquez-Acosta C, et al. Colonization by fecal extended-spectrum beta-lactamase-producing Enterobacteriaceae and surgical site infections in patients with cancer undergoing gastrointestinal and gynecologic surgery. Am J Infect Control 2019; 47: 916-921.
Files
IssueVol 16 No 4 (2024) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijm.v16i4.16307
Keywords
Gastrointestinal neoplasms; Antimicrobial stewardship; Antibiotic prophylaxis; Biliary tract; Drug resistance; Microbial; Colorectal surgery
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Yildiz M, Buyukkoruk M, Arslan S, Gokalp U, Bostanci H, Dikmen K, Buyukkasap C, Ozger H, Dizbay M. Evaluating the frequency and risk factors of multidrug-resistant bacteria in biliary samples. Iran J Microbiol. 2024;16(4):484-489.